Wednesday, May 11, 2016
Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers
Not all stuffy noses are alike. That’s the conclusion of a research study by Tomassen and colleagues published this month in the Journal of Allergy and Clinical Immunology (J Allergy Clin Immunol 2016; 137(5): 1449-1456). Despite affecting one out of eight Americans, little is really known about chronic rhinosinusitis and treatment is often really frustrating. To figure out more personalized approaches to tackling chronic rhinosinusitis, Tomassen’s group collected tissue samples from patients with chronic rhinosinusitis, as well as people who had no history of chronic rhinosinusitis. They then analyzed 14 bio-markers to see if they could find groups of patients who had particular patterns of inflammation.
Ten distinct endotypes, or subgroups linked to biological pathways, that correlated to different features were identified. The biggest differentiator was the level of IL-5. Patients with higher levels were more likely to have polyps (outgrowths of the mucous membranes associated with more severe disease) and/or concomitant asthma. Combined with the other markers, these findings can help identify people who would be expected to respond to different types of medications. Since there are new medications that target individual inflammatory markers, such as IL-5, this information can provide valuable insight into personalizing an approach to reduce the frustration in treating chronic rhinosinusitis.